Theratechnologies Inc.

2310 Alfred-Nobel Boulevard
Saint-Laurent
Quebec
H4S 2A4
Canada

Tel: 514-336-7800
Fax: 514-336-7242

Email: webinfo@theratech.com.

Show jobs for this employer

201 articles with Theratechnologies Inc.

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that management will be presenting at the following upcoming virtual investor conferences. B. Riley Securities Liver Disease Therapeutic s Day Thursday, October 29, 2020 Panel discussion with Dr. Christian Marsolais, Senior Vice President and Chief Medi

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors. “Both Andrew and Alain bring tremendous value to our Board. They are well-recognized and respected by their peers in the business community for their kn

  • Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced its financial results for the third quarter of fiscal year 2020 ended August 31, 2020.

  • Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the United States Patent and Trademark Office has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis and/or Nonalcoholic Fatty Liver Disease in patients using tesamorelin.

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, will present at the H.C. Wainwright 4th Annual NASH Investor Conference on Monday, October 5, 2020 at 4:30 p.m. ET.

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced select preliminary financial results for the third quarter ended August 31, 2020. For the third quarter of fiscal year 2020, the company expects consolidated net revenues to be between $13.8 million and $14.2 million compared to $16.1 million for the third quarter

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in the gene

  • Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that Trogarzo® will be commercially available in Germany as of tomorrow through its subsidiary, Theratechnologies Europe Limited.

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce new data that further support the potential role of tesamorelin in the treatment of HIV-associated nonalcoholic steatohepatitis (NASH). 

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today held its annual meeting of shareholders. As part of the meeting, shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term and elected KPMG LLP, as the Company’s auditors for the current fiscal year. All candidates proposed for the position of directors were elected in the follow

  • -Total product revenues of $17.2M, a 10% increase compared to Q2 2019 and 9% increase compared to Q1 2020- -Trogarzo ® net revenues up 13.2% and combined EGRIFTA ® , EGRIFTA SV ® net revenues up 7.3% over Q2 2019- -Supply chain and product inventory remain unaffected by COVID-19 pandemic- MONTREAL, July 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced its

  • sBLA expected to be filed in early 2022 Seven-day multidose vial and room temperature stability allow for the potential use of tesamorelin with a multidose pen injector

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 23 rd International AIDS Conference virtual meeting, demonstrates that ibalizumab is active in vitro against group A and group B HIV-2. Ibalizumab in vitro activity against HIV-2 The objective of the study, conducted by a team of researchers at Bichat-Claude Bernard Hospital and Sa

  • Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor Curcumin shows increased anticancer activity when conjugated to proprietary peptide SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments

  • Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904 New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II MONTREAL, May 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that management will present at the RBC Global Healthcare Conference on Tuesday, May 19, 2020 at 9:10 a.m. ET.  The audio portion of management’s live and archived webcast can be accessed from https://www.veracast.com/webcasts/rbc/healthcare2020/96103453385.cfm . The archived webcast will be available one hour after t

  • TH1902 and TH1904 more effective and safer in vivo compared to current standard ovarian cancer treatments New data presented during the AACR Virtual Annual Meeting

  • Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it will make an oral presentation on new results from its sortilin targeting oncology platform during a virtual session of the annual meeting of the American Association for Cancer Research (AACR).

  • Theratechnologies Inc., or Theratechnologies (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced today that Paul Lévesque, the current President and Chief Executive Officer of Theratechnologies, was granted 487,421 stock options, or Options, to purchase an aggregate of 487,421 common shares of Theratechnologies under Nasdaq Listing Rule 5635(c)(4). The grant was made outside of Theratechnologies’ existing share option p

  • Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced its financial results for the first quarter ended February 29, 2020.